Lupin Pharma Ka USFDA Kamaal! Diabetes Drug Ko Mili Approval, Lekin Stock Mein Dikhi Halki Kami?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Lupin Pharma Ka USFDA Kamaal! Diabetes Drug Ko Mili Approval, Lekin Stock Mein Dikhi Halki Kami?
Overview

Arre bhai, Lupin Pharma ke liye USFDA se ek badi khabar aayi hai! Unko unke diabetes waale tablets, Dapagliflozin and Metformin Hydrochloride extended-release tablets ke liye USFDA ki approval mil gayi hai. Isse US market mein unka anti-diabetic business aur strong hoga.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

So, USFDA ne Lupin ke Dapagliflozin and Metformin Hydrochloride extended-release tablets ko approve kar diya hai. Yeh approval multiple strengths mein mili hai, jaise 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, aur 10 mg/1,000 mg. Ek 2.5 mg/1,000 mg waale variant ko tentative approval mili hai.

Yeh medicine Xigduo XR ke jaisi hi hai, jo type 2 diabetes ke liye kaafi use hoti hai. Is approval se Lupin ki US mein anti-diabetic market mein position aur mazboot hogi. America jaise bade pharma market mein yeh ek important step hai.

Ab baat karte hain dusri strategy ki. Isi mahine, Lupin ki Netherlands wali subsidiary, Nanomi BV, Philippines ki Multicare Pharmaceuticals Philippines Inc. (MPPI) mein aur 43.38% stake khareed rahi hai. Yeh deal $39.6 million tak ja sakti hai. Isse Nanomi ka MPPI par control aur badh jayega, jahan unka pehle se 56.28% ownership hai.

Company ka kehna hai ki Philippines mein yeh investment unke emerging markets ko streamline karne aur long-term growth ke liye bahut zaroori hai. Isse business processes ko optimize karne aur market access improve karne mein help milegi.

Lekin interesting baat yeh hai ki, itni achhi khabron ke baad bhi, Lupin ka share price Wednesday, April 8 ko thoda neeche dikha. NSE par stock 0.18% gir kar ₹2,294.10 par close hua.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.